Currently, the clinical interventions for patients with BC-bone metastasis (BC-BM) are bisphosphonates (BPs) or denosumab (an anti-receptor activator of nuclear factor kappa B ligand (RANKL) monoclonal antibody), which disrupt the vicious cycle by targeting osteoclasts [6]. Here, TNFSF11 is linked to bone metastasis.